Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobolimab + Dostarlimab in pediatric and young adult solid tumors
NCT06521567Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, open-label trial of cobolimab in melanoma, Hodgkin lymphoma (HL), high-grade glioma (HGG) and 9 more (2 arms), sponsored by GSK. Primary endpoints: Dose Limiting Toxicities at 42 days, Treatment-Emergent Adverse Events at 46 months and 5 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
cobolimab
03
Conditions
melanomaHodgkin lymphoma (HL)high-grade glioma (HGG)low-grade glioma (LGG)glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT06521567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06521567.